Scenarios that move ABUS

Arbutus Biopharma Corporation - Common Stock

Scenarios that move ABUS: 2 analyses, 0 positive, 2 negative.

1. 2026-09-29 · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▼ · impact -30 · confidence low · horizon weeks
2. 2026-09-23 · Ionis reports positive late-stage results for two partnered drugs — ▼ · impact -34 · confidence low · horizon weeks

All scenarios · Run a scenario · Pricing